Dimensional Fund Advisors LP Takes $371,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)

Dimensional Fund Advisors LP acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 118,241 shares of the company's stock, valued at approximately $371,000. Dimensional Fund Advisors LP owned 0.12% of Acelyrin as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Barclays PLC raised its position in Acelyrin by 208.8% in the third quarter. Barclays PLC now owns 96,408 shares of the company's stock worth $475,000 after acquiring an additional 65,188 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Acelyrin by 36.9% in the 3rd quarter. Franklin Resources Inc. now owns 128,591 shares of the company's stock worth $634,000 after purchasing an additional 34,642 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Acelyrin by 71.0% in the 4th quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock worth $83,000 after purchasing an additional 11,040 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Acelyrin by 146.0% in the 4th quarter. American Century Companies Inc. now owns 78,868 shares of the company's stock worth $248,000 after purchasing an additional 46,802 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Acelyrin during the fourth quarter valued at approximately $567,000. Institutional investors and hedge funds own 87.31% of the company's stock.

Insider Activity at Acelyrin

In other news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the transaction, the chief executive officer now directly owns 671,753 shares of the company's stock, valued at $1,840,603.22. This trade represents a 2.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 13.60% of the stock is currently owned by corporate insiders.

Acelyrin Stock Up 1.8%

Acelyrin stock traded up $0.04 during mid-day trading on Tuesday, hitting $2.27. The company's stock had a trading volume of 4,076,442 shares, compared to its average volume of 1,233,146. The stock has a market capitalization of $229.17 million, a P/E ratio of -0.92 and a beta of 1.07. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.25. The stock's fifty day moving average price is $2.40 and its two-hundred day moving average price is $2.93.

Acelyrin (NASDAQ:SLRN - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.40. Equities analysts expect that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.